Alterity Therapeutics (ATHE) Other Non-Current Liabilities (2009 - 2025)
Alterity Therapeutics (ATHE) posted quarterly Other Non-Current Liabilities of $617156.7 for Q4 2025, up 60.79% year-over-year from $383839.2 in Q4 2024, and up 10.02% quarter-over-quarter from $560960.6 in Q2 2025.
Alterity Therapeutics (ATHE) Other Non-Current Liabilities (2009 - 2025) Analysis & Trends
Alterity Therapeutics' Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $617156.7 for Q4 2025.
- In Q4 2025, Other Non-Current Liabilities rose 60.79% year-over-year to $617156.7; the TTM figure through Dec 2025 stood at $617156.7 (up 60.79% YoY), while the FY2025 annual figure was $560960.6, up 60.39% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $617156.7, up from $560960.6 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $617156.7 in Q4 2025, with the low at $5307.0 in Q2 2024.
- The 5-year median for Other Non-Current Liabilities is $436594.4 (2021), against an average of $379120.2.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Liabilities plunged 98.45% in 2023, then surged 10470.22% in 2025.
- Alterity Therapeutics' Other Non-Current Liabilities stood at $446642.3 in 2021, then rose by 2.9% to $459591.4 in 2022, then declined by 7.19% to $426546.5 in 2023, then slipped by 10.01% to $383839.2 in 2024, then jumped by 60.79% to $617156.7 in 2025.
- Business Quant data shows ATHE's Other Non-Current Liabilities at $617156.7 in Q4 2025, $560960.6 in Q2 2025, and $383839.2 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Alterity Therapeutics | 48.56 Mn | 16.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 617,156.71 |
| Jun 30, 2025 | 560,960.57 |
| Dec 31, 2024 | 383,839.17 |
| Jun 30, 2024 | 5,306.99 |
| Dec 31, 2023 | 426,546.54 |
| Jun 30, 2023 | 7,292.02 |
| Dec 31, 2022 | 459,591.35 |
| Jun 30, 2022 | 470,063.26 |
| Dec 31, 2021 | 446,642.34 |
| Jun 30, 2021 | 413,802.99 |
| Dec 31, 2020 | 517,509.86 |
| Jun 30, 2020 | 401,142.98 |
| Dec 31, 2019 | 372,609.86 |
| Jun 30, 2019 | 24,499.72 |
| Dec 31, 2018 | 394.64 |
| Jun 30, 2018 | 445,662.33 |
| Dec 31, 2017 | 450,004.45 |
| Jun 30, 2017 | 524.34 |
| Dec 31, 2016 | 547,407.08 |
| Jun 30, 2016 | 454.59 |